Basis: Four-quarter free cash flow / FMP quote market capitalization × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The free cash flow yield is N/A as of 2026-10-06T18:05:35.770Z.
Calculation as of: 2026-10-06T18:05:35.770Z.
Quote observation: 2026-10-06T18:00:04.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 8c4e2329810c85a761ec37603feeca28f75a2d8b2781946fcb814d6340a505d6
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FREE CASH FLOW YIELD
N/A
Market Cap
$7.25M
Free Cash Flow Yield
N/A
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$7.13M
Free Cash Flow Yield
N/A
TTM Avg
17.66%
3Y Avg
16.46%
5Y Avg
16.46%
Market Cap
$7.55M
Free Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$7.02M
Free Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | FREE CASH FLOW YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Skye Bioscience, Inc. (SKYE) | $7.29M | N/A | N/A | N/A | N/A |
| InMed Pharmaceuticals Inc. (INM)vs › | $7.25M | N/A | 0.00% | 0.00% | 0.00% |
| Longeveron Inc. (LGVN)vs › | $7.21M | N/A | N/A | N/A | N/A |
| Mangoceuticals, Inc. (MGRX)vs › | $7.13M | N/A | N/A | N/A | N/A |
| Co-Diagnostics, Inc. (CODX)vs › | $7.13M | N/A | 17.66% | 16.46% | 16.46% |
| KALA BIO, Inc. (KALA)vs › | $7.07M | N/A | N/A | N/A | N/A |
| Quince Therapeutics, Inc. (QNCX)vs › | $7.55M | N/A | N/A | N/A | N/A |
| NeuroSense Therapeutics Ltd. (NRSN)vs › | $7.02M | N/A | N/A | N/A | N/A |
| Exicure, Inc. (XCUR)vs › | $6.95M | N/A | 0.04% | 0.04% | 0.04% |
| Bolt Biotherapeutics, Inc. (BOLT)vs › | $6.94M | N/A | N/A | N/A | N/A |
FCF Yield
N/A
Earnings Yield
N/A
Dividend Yield
N/A
Formula: FCF Yield = (Free Cash Flow / Market Cap) × 100
How FCF Yield is used:
FCF vs earnings: Differences between FCF yield and earnings yield can reflect capital expenditures, working capital changes, and other non-cash accounting items.
FCF Yield measures free cash flow relative to market capitalization. It compares cash generation after capital expenditures with the equity value of the company.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
